Immunovant, Inc.
IMVT
$23.35
-$0.32-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.61M | -106.45M | -111.12M | -109.12M | -87.15M |
| Total Depreciation and Amortization | 107.00K | 109.00K | 99.00K | 89.00K | 80.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.53M | 11.71M | 11.68M | 12.72M | 13.52M |
| Change in Net Operating Assets | -15.44M | -16.01M | -1.04M | 7.67M | -2.65M |
| Cash from Operations | -117.41M | -110.64M | -100.39M | -88.65M | -76.20M |
| Capital Expenditure | -- | -201.00K | -180.00K | -196.00K | -182.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -201.00K | -180.00K | -196.00K | -182.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.92M | 450.93M | 2.46M | 730.00K | 686.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -319.00K | -- | -- | -- |
| Cash from Financing | 2.92M | 450.61M | 2.46M | 730.00K | 686.00K |
| Foreign Exchange rate Adjustments | -566.00K | -488.00K | -149.00K | 1.05M | 335.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.06M | 339.29M | -98.26M | -87.06M | -75.36M |